NCT05910125

Aspirin Combined With Clopidogrel Versus Intravenous Alteplase for Acute Minor Stroke

Aspirin Combined With Clopidogrel Versus Intravenous Alteplase for Acute Minor Stroke: An Open-label, Blinded Endpoint, Randomized Controlled Trial

• Status: Not Yet Recruiting
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 472 (estimated)
• Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Academic / Other
• Sex: All
• Age: 40 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

An open-label, blinded endpoint, randomized controlled trial that includes patients diagnosed with non-disabling, non-large vessel occlusion, acute minor stroke within 4.5 hours of onset. Eligible participants would be randomly assigned to the thrombolysis group (intravenous alteplase) and the dual antiplatelet group (oral aspirin plus clopidogrel). The primary outcome is the proportion of the excellent functional outcome (modified Rankin scale 0-1) at 90 days.

Conditions

• Ischemic Stroke

Interventions

Type	Name	Description
DRUG	Aspirin	See arm/group descriptions.
DRUG	Clopidogrel	See arm/group descriptions.
DRUG	Alteplase	See arm/group descriptions.

Timeline

• Start date: 2023-07-01
• Primary completion: 2027-07-01
• Completion: 2027-07-01
• First posted: 2023-06-18
• Last updated: 2023-06-18

Locations

1 site across 1 country: China